Cognition Therapeutics, Inc. (CGTX)
Develops experimental drugs to treat Alzheimer's and age-related brain diseases.
$0.92-0.03%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago+38.5%
The outlook
CGTX is trading near its 52-week lows, well below both its 50- and 200-day moving averages, reflecting weak near-term momentum. Analyst coverage leans bullish with an average price target suggesting substantial upside, though the stock's current positioning and overall StockGlow score remain decidedly bearish.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range11% of the way from its 52-week low to high
Price targetAvg target +279% vs current price
Analyst price target
~12-month · 4 analysts$3.50average target+279.0% vs now
Now $0.92
Low $3.00High $4.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$82.7M
52-wk high
$3.83
52-wk low
$0.55
50-day avg
$1.16
200-day avg
$1.29
Trailing P/E
—